DeCure for Cortical dysplasia, complex, with other brain malformations 12
DeCure's autonomous Rare AI scientist is researching a drug-repurposing hypothesis for cortical dysplasia, complex, with other brain malformations 12 — screening already-approved drugs against its 1-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleCortical dysplasia, complex, with other brain malformations 12 maps to a 1-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for cortical dysplasia, complex, with other brain malformations 12 is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
calmodulin regulated spectrin associated protein 1 (CAMSAP1) — CAMSAP1 is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet gtpdrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 6QUS · 3.7 Å · ligand GUANOSINE-5'-TRIPHOSPHATE (GTP). Experimental structure, not a prediction.
What the evidence adds up to
The 2012 review proposes a classification for malformations of cortical development based on advances in molecular biology, genetics and imaging, but does not report any treatment outcomes or drug trials. The 2007 chapter describes the genetic basis of several cortical malformations, including heterotopia and lissencephaly, and notes that brain malformations are a relatively common cause of refractory epilepsy and mental retardation, but again provides no therapeutic data.
A 2003 surgical series of 126 patients with malformations of cortical development, drawn from 321 consecutive operated patients, reports outcomes after focal cortical resection. The largest subgroup was 81 patients with focal cortical dysplasia, further classified as 42 architectural dysplasias, 12 cytoarchitectural dysplasias and 27 Taylor's focal cortical dysplasias. Other malformation types included periventricular heterotopia (nine patients), polymicrogyria (three patients), hemimegalencephaly (one patient) and subcortical band heterotopia (one patient). After at least one year of follow-up, the best seizure-free rate (Engel class Ia) was 69% in patients with Taylor's type dysplasia, compared with 45% for cytoarchitectural dysplasia and 49% for architectural dysplasia. Magnetic resonance imaging was unhelpful in 17 of 81 patients with focal cortical dysplasia and in 7 of 31 with neuronal heterotopia. The 1978 report describes four histologically confirmed cases of cortical malformation with heterotopia, discussing computed tomography findings but no treatment.
No abstract in this set reports any drug treatment, repurposed or otherwise, for cortical dysplasia with other brain malformations. What is missing is any clinical trial of pharmacological therapy for this specific condition, any patient stratification beyond surgical candidacy, and any funding directed at drug discovery or repurposing for the disorder.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Brain · 2012 · 1076 citations · open access
A developmental and genetic classification for malformations of cortical development: update 2012
AbstractMalformations of cerebral cortical development include a wide range of developmental disorders that are common causes of neurodevelopmental delay and epilepsy. In addition, study of these disorders contributes greatly to the understanding of normal brain development and its perturbations. The rapid recent evolution of molecular biology, genetics and imaging has resulted in an explosive increase in our knowledge of cerebral cortex development and in the number and types of malformations of cortical development that have been reported. These advances continue to modify our perception of these malformations. This review addresses recent changes in our perception of these disorders and proposes a modified classification based upon updates in our knowledge of cerebral cortical development.
Epileptic Disorders · 2003 · 45 citations · open access
Focal cortical resection in malformations of cortical development
AbstractMalformations of cortical development may be associated with drug-resistant partial epilepsy suitable for surgical therapy. From the anatomopathological point of view, this categorisation has been used in reference to a wide range of alterations of the cortical mantle. Focal cortical dysplasias represent the main group of malformations of cortical development, but there are also other types of alterations, such as heterotopias, double cortex or polymicrogyria. Defining candidacy for surgical therapy and tailored resection requires thorough pre-surgical evaluation so that the approach will be individualised for each patient. We present our series of 126 patients with malformation of cortical development selected from 321 consecutively operated patients. Within this group encompassing different types of malformation of cortical development, including periventricular heterotopia (nine patients), polymicrogyria (three patients), hemimegalencephaly (one patient) and subcortical band heterotopia (one patient), the largest group was 81 individuals with focal cortical dysplasia. For this last group, we propose a simplified classification defining 42 architectural dysplasias, 12 cytoarchitectural dysplasias and 27 Taylor's focal cortical dysplasias. In addition, at routine neuropathological investigation, the only morphological alteration shown by 31 patients was diffuse neuronal heterotopia. All patients underwent scalp EEG and video-EEG, and 75 patients (59.5%) also underwent stereo-EEG. Magnetic resonance imaging and stereotactic stereoscopic angiography represented the indispensable premises for further studies, in particular stereo-EEG, and for planning surgery and tailoring resection. Magnetic resonance imaging was unhelpful in 17 out of 81 patients with focal cortical dysplasia and in seven out of 31 with neuronal heterotopia, while signal alterations were present in all other cases. Common characteristics corresponding to clinical-histopathological homogeneous subgroups were found within the focal cortical dysplasia group. In patients with architectural dysplasia, the epileptogenic zone was mainly in the temporal lobe and there was a lower seizure frequency than in patients with Taylor's focal cortical dysplasia. Patients with Taylor's type had an epileptogenic zone that was mainly extra-temporal, and a distinctive interictal stereo-EEG. The best outcome was observed in patients with Taylor's type dysplasia: 69% seizure-free (Engel class Ia) after at least 1 year of follow-up, compared with 45% of cytoarchitectural dysplasia and 49% of architectural dysplasia patients.
Journal of Computer Assisted Tomography · 1978 · 32 citations
Malformation of the Cerebral Cortex with Heterotopia of the Gray Matter
AbstractDevelopmental malformation of the cerebral cortex with heterotopia of the gray matter is a rare condition. It can present as unilateral megalencephaly, a localized mass, or focal cortical dysplasia. Four histologically confirmed cases are described in this report, and the findings from computed tomography as well as from other radiological diagnostic procedures are discussed.
The Genetic Basis of Human Cerebral Cortical Malformations
AbstractMalformations of cortical development occur when the normal process of brain development is disrupted. With the widespread use of high-resolution neuroimaging, brain malformations are increasingly being recognized as a relatively common cause orefractory epilepsy, mental retardation, and other neurological disorders. The molecular and genetic bases of many cortical malformations have been elucidated in recent years, both expanding our understanding of the underlying biological processes in brain development and informing our approach to these disorders in clinical practice. This chapter highlights some of these malformations, including disorders of microcephaly, gray matter hetero-topia, lissencephaly syndromes, and polymicrogyria.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
